Tag: Anticoagulants
AHA: Oral Milvexian Promising for Prevention of VTE
In patients undergoing knee arthroplasty, postoperative incidence of venous thromboembolism lower with milvexian versus enoxaparin
Therapeutic Heparin May Benefit Moderately Ill COVID-19 Inpatients
Among those with increased D-dimer levels, no reduction seen in primary composite outcome at 28 days, but odds of death decreased
COVID-19 Outcomes in Critically Ill No Better With Full-Dose Heparin
For patients hospitalized with COVID-19 who are not critically ill, therapeutic-dose anticoagulation is beneficial
Racial/Ethnic Disparities Seen in Anticoagulant Initiation for A-Fib
Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use
Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
ASH Suggests Not Using Outpatient Thromboprophylaxis for COVID-19
For discharged patients without suspected or confirmed VTE or other indication for anticoagulation, panel suggests not using anticoagulants
Prophylactic Anticoagulation Aids Hospitalized COVID-19 Patients
Prophylactic-dose anticoagulation, but not treatment-dose anticoagulation, associated with lower 60-day mortality
Guidance Issued for Managing CVST After COVID-19 Vaccination
CVST with thrombocytopenia reported after COVID-19 vaccine with adenoviral vector; management similar to heparin-induced thrombocytopenia
Adding Aspirin May Up Risk for Patients on DOAC for A-Fib/VTE
Among patients with a-fib and/or VTE, about one-third received ASA in addition to a DOAC with no clear indication for ASA
Prophylactic Anticoagulation May Cut COVID-19 Mortality
Lower 30-day mortality, no increase in serious bleeding events seen among COVID-19 inpatients receiving early prophylactic anticoagulation
